HLA-C and neoplasm: Notably, this strategy allowed for the flexible incorporation of multiple MHC class I‐ or II‐restricted peptide neoantigens (M21, M27, and M33), which facilitated efficient DC‐mediated antigen presentation, thereby enhancing the magnitude of CTL responses and promoting tumor regression.